Peptide Education Manager
Edit Tesamorelin
Name
Scientific / Common Name
Alternative Names
Slug (url-safe, unique)
Short Description (shown on cards)
A growth hormone releasing hormone analog with a narrow FDA-approved indication for visceral fat reduction in a specific patient population.
Overview — What Is It? (paragraphs)
Tesamorelin is a synthetic GHRH analog that, under the brand name Egrifta, is FDA-approved specifically for the reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy — a defined medical condition in a defined population. This narrow, approved indication is supported by randomized controlled clinical trials. Outside of that specific approved population and indication, use of tesamorelin for general body composition or wellness goals is considered off-label and has a much more limited, less rigorous evidence base. Understanding the distinction between tesamorelin's one well-studied, approved use and its broader off-label research interest is important context for evaluating this therapy.
Why Being Studied (one item per line)
Visceral fat reduction (within the approved indication) Growth hormone pathway stimulation Body composition research more broadly (off-label) Metabolic marker changes in clinical trial populations
How It May Work
Tesamorelin binds to GHRH receptors on the pituitary gland, stimulating growth hormone release through the body's natural signaling pathway. In clinical trials within its approved population, this growth hormone stimulation was associated with measurable reductions in visceral adipose tissue.
Mechanism Pathway Steps (one per line)
Tesamorelin Pituitary GHRH receptor activation Growth hormone release & downstream lipolytic signaling Visceral fat reduction demonstrated in its approved clinical population
Evidence Rating
Established / Approved Use
Strong Human Evidence
Moderate Human Evidence
Early Human Evidence
Preclinical Evidence
Emerging / Limited Evidence
Human Evidence
Randomized controlled clinical trials supported FDA approval of tesamorelin (Egrifta) specifically for reducing excess visceral fat in HIV-infected patients with lipodystrophy. Evidence for broader, off-label body composition use outside this population is more limited.
Preclinical Evidence
Preclinical pharmacology research characterized GHRH receptor activity and growth hormone-releasing effects prior to and alongside human trials.
What We Don't Know Yet
How tesamorelin performs for general body composition goals outside its specific approved population has not been established through the same rigorous trial process that supported its approved indication.
Research Area Cards (format: Title: description — one per line)
Metabolic Health: The approved indication centers on visceral fat reduction, a key metabolic health marker. Muscle & Body Composition: Growth hormone pathway stimulation has broader research interest in body composition contexts.
Why Might Someone Discuss This With Their Provider?
Someone evaluating visceral fat or growth hormone pathway therapies may want to understand both the approved, narrow indication and the broader off-label research context for tesamorelin.
Regulatory Status
Tesamorelin (brand name Egrifta) is FDA-approved specifically for reducing excess visceral abdominal fat in HIV-infected patients with lipodystrophy. Use outside that approved indication and population is considered off-label.
Important Considerations
This compound's one clearly approved use is narrow and population-specific. Off-label use should be discussed as an individualized decision with a licensed healthcare provider, who can review appropriateness, risks, and monitoring needs.
Related Peptide Slugs (one per line)
sermorelin cjc-1295-ipamorelin
Is Combination Product?
Categories / Goals
Recovery & Repair
Metabolic Health
Weight Management
Performance
Muscle & Body Composition
Sleep & Recovery
Cognitive Health
Stress & Mood
Longevity & Healthy Aging
Cellular Energy
Skin, Hair & Aesthetics
Sexual Wellness
Search Tags (comma separated)
Last Reviewed Date
Display Order
Published
Featured
Save Peptide